The management of patients with metastatic prostate cancer during the COVID-19 pandemic

During the ongoing global pandemic of coronavirus disease 2019 (COVID-19), the benefit of treating patients with cancer must be weighed against the COVID-19 infection risks to patients, staff and society. Prostate cancer is one of the most common cancers among men and raises particular interest duri...

Descripción completa

Detalles Bibliográficos
Autores principales: Assi, Tarek, Ibrahim, Nathalie, K Abboud, Rita-Maria, Kattan, Clarisse, Rassy, Elie, Nemr, Elie, Kattan, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2020
Materias:
Special Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7426764/
https://www.ncbi.nlm.nih.gov/pubmed/32412310
http://dx.doi.org/10.2217/fon-2020-0361
_version_ 1783570749942923264
author Assi, Tarek
Ibrahim, Nathalie
K Abboud, Rita-Maria
Kattan, Clarisse
Rassy, Elie
Nemr, Elie
Kattan, Joseph
author_facet Assi, Tarek
Ibrahim, Nathalie
K Abboud, Rita-Maria
Kattan, Clarisse
Rassy, Elie
Nemr, Elie
Kattan, Joseph
author_sort Assi, Tarek
collection PubMed
description During the ongoing global pandemic of coronavirus disease 2019 (COVID-19), the benefit of treating patients with cancer must be weighed against the COVID-19 infection risks to patients, staff and society. Prostate cancer is one of the most common cancers among men and raises particular interest during the pandemic as recent reports show that the TMPRSS2 (and other serine proteases), which facilitate the entry, replication and budding of the virion from a cell, can be inhibited using androgen deprivation therapy. Nevertheless, patients with metastatic prostate cancer commonly receive chemotherapy which may compromise their immune system. This paper aims to address the current status of the COVID-19 in patients with cancer overall and suggests an optimal approach to patients with metastatic prostate cancer.
format Online
Article
Text
id pubmed-7426764
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Future Medicine Ltd
record_format MEDLINE/PubMed
spelling pubmed-74267642020-08-21 The management of patients with metastatic prostate cancer during the COVID-19 pandemic Assi, Tarek Ibrahim, Nathalie K Abboud, Rita-Maria Kattan, Clarisse Rassy, Elie Nemr, Elie Kattan, Joseph Future Oncol Special Report During the ongoing global pandemic of coronavirus disease 2019 (COVID-19), the benefit of treating patients with cancer must be weighed against the COVID-19 infection risks to patients, staff and society. Prostate cancer is one of the most common cancers among men and raises particular interest during the pandemic as recent reports show that the TMPRSS2 (and other serine proteases), which facilitate the entry, replication and budding of the virion from a cell, can be inhibited using androgen deprivation therapy. Nevertheless, patients with metastatic prostate cancer commonly receive chemotherapy which may compromise their immune system. This paper aims to address the current status of the COVID-19 in patients with cancer overall and suggests an optimal approach to patients with metastatic prostate cancer. Future Medicine Ltd 2020-05-15 2020-07 /pmc/articles/PMC7426764/ /pubmed/32412310 http://dx.doi.org/10.2217/fon-2020-0361 Text en © 2020 Future Medicine Ltd This work is licensed under the Creative Commons Attribution 4.0 License (http://creativecommons.org/licenses/by/4.0/)
spellingShingle Special Report
Assi, Tarek
Ibrahim, Nathalie
K Abboud, Rita-Maria
Kattan, Clarisse
Rassy, Elie
Nemr, Elie
Kattan, Joseph
The management of patients with metastatic prostate cancer during the COVID-19 pandemic
title The management of patients with metastatic prostate cancer during the COVID-19 pandemic
title_full The management of patients with metastatic prostate cancer during the COVID-19 pandemic
title_fullStr The management of patients with metastatic prostate cancer during the COVID-19 pandemic
title_full_unstemmed The management of patients with metastatic prostate cancer during the COVID-19 pandemic
title_short The management of patients with metastatic prostate cancer during the COVID-19 pandemic
title_sort management of patients with metastatic prostate cancer during the covid-19 pandemic
topic Special Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7426764/
https://www.ncbi.nlm.nih.gov/pubmed/32412310
http://dx.doi.org/10.2217/fon-2020-0361
work_keys_str_mv AT assitarek themanagementofpatientswithmetastaticprostatecancerduringthecovid19pandemic
AT ibrahimnathalie themanagementofpatientswithmetastaticprostatecancerduringthecovid19pandemic
AT kabboudritamaria themanagementofpatientswithmetastaticprostatecancerduringthecovid19pandemic
AT kattanclarisse themanagementofpatientswithmetastaticprostatecancerduringthecovid19pandemic
AT rassyelie themanagementofpatientswithmetastaticprostatecancerduringthecovid19pandemic
AT nemrelie themanagementofpatientswithmetastaticprostatecancerduringthecovid19pandemic
AT kattanjoseph themanagementofpatientswithmetastaticprostatecancerduringthecovid19pandemic
AT assitarek managementofpatientswithmetastaticprostatecancerduringthecovid19pandemic
AT ibrahimnathalie managementofpatientswithmetastaticprostatecancerduringthecovid19pandemic
AT kabboudritamaria managementofpatientswithmetastaticprostatecancerduringthecovid19pandemic
AT kattanclarisse managementofpatientswithmetastaticprostatecancerduringthecovid19pandemic
AT rassyelie managementofpatientswithmetastaticprostatecancerduringthecovid19pandemic
AT nemrelie managementofpatientswithmetastaticprostatecancerduringthecovid19pandemic
AT kattanjoseph managementofpatientswithmetastaticprostatecancerduringthecovid19pandemic

Ejemplares similares